Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23880241 | 0.79 | MAP3K14 (0.37) | KMT2AMAP3K14CYP2D6HRH3GRM4 | |
| SCHEMBL2119388 | 0.73 | KDM4E (0.50) | ALDH1A1MEN1KMT2AF2PLAU | |
| SCHEMBL19010745 | 0.72 | L3MBTL1 (0.49) | L3MBTL1ALDH1A1MEN1KMT2AAR | |
| SCHEMBL3058408 | 0.71 | HTT (0.38) | ALDH1A1MEN1KMT2AF2PLAU | |
| SCHEMBL6476531 | 0.69 | BAZ2B (0.42) | ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL21961311 | 0.68 | NR2E1 (0.39) | L3MBTL1ALDH1A1KMT2AMAP3K14GRM4 | |
| SCHEMBL30530971 | 0.68 | ALDH1A1 (0.47) | L3MBTL1ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL27900268 | 0.67 | CYP1A2 (0.35) | ALDH1A1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL28959660 | 0.66 | PRSS1 (0.37) | ALDH1A1MEN1KMT2AF2PLAU | |
| SCHEMBL18029670 | 0.66 | LMNA (0.46) | L3MBTL1ALDH1A1MEN1KMT2AELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136311-B2 | Heteroaromatic derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-05 | — | — | US | disclosed |
| EP-3478675-B1 | HETEROAROMATIC DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11136311-B2 | Heteroaromatic derivatives as NIK inhibitors | NFKBIA, IKBKG, IKBKE | L3MBTL1 2728/4885ALDH1A1 3872/4885MEN1 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.